|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | |  | | PSNC Newsletter | | Friday 25th February 2022 | | |  | | |  |  |  | | --- | --- | --- | |  |  |  | |  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector. In this update: Year 4 CPCF negotiations begin; confirm your choice of CPCS IT system; one week left for PhAS review applications; SSPs extended.Negotiations on CPCF arrangements for 2022/23 commence Formal tripartite negotiations on the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 – the fourth year of the agreed five-year CPCF deal – have now begun. The negotiations are taking place between PSNC and the Department of Health and Social Care (DHSC), supported by NHS England and NHS Improvement (NHSE&I).  The discussions will take into account the progress made to date, which has been partly impacted by the COVID-19 pandemic, as well as the recent joint [**Annual Review process**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=049ea85f3f&e=d19e9fd41c), where PSNC raised serious concerns around the capacity available within community pharmacy, and the sector's funding.  Negotiations will remain confidential as usual, but we will update contractors on the outcomes of these negotiations as soon as we can.  [**Read more, including a statement from PSNC's Vice-chair**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=0df71d2ef9&e=d19e9fd41c) CPCS IT deadline approaching: Have you confirmed your choice of system? The national procurement of IT support for the NHS Community Pharmacist Consultation Service (CPCS) is due to stop at the end of March 2022. Contractors that wish to continue providing CPCS must, therefore, confirm their choice of CPCS IT system in February 2022. Failure to do so could impact referrals and service continuity.  The [**CPCS IT switching guide**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=b8f2960296&e=d19e9fd41c) explains the options are:   1. **Switch** to another CPCS IT provider (you must inform them well in advance so they can confirm the switch has been successful); or 2. **Stay** with existing CPCS IT provider (you must notify them so they can confirm a new service agreement with you).   [**View the verified CPCS IT system suppliers and further guidance**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=39e933372b&e=d19e9fd41c) Just one week left to complete Pharmacy Access Scheme 2022 review application Contractors eligible to apply for a Pharmacy Access Scheme (PhAS) review are reminded that they have until **midnight on 4th March 2022** to complete their applications on the dedicated NHSE&I web review portal.  Those applying for a review are strongly encouraged to read [**PhAS: contractor guidance on submitting an eligibility review application – distance grounds only**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=a15088df20&e=d19e9fd41c) before starting their applications. Please note, it is important to gather all the evidence you need for an application before you start it.  [**Find out more about the review application process**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=eb624e80f6&e=d19e9fd41c) Extension to SSPs for Paracetamol suppositories and Lipitor® chewable tablets DHSC has confirmed the extension of several Serious Shortage Protocols (SSPs):   |  |  | | --- | --- | | **SSP number and product** | **Revised end date** | | [**SSP015: Paracetamol 120mg & 240mg suppositories**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=6bd3a807f6&e=d19e9fd41c) | 4th March 2022 | | [**SSP016: Lipitor® 10mg chewable tablets**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=dde2cf674f&e=d19e9fd41c) | 18th March 2022 | | [**SSP017: Lipitor® 20mg chewable tablets**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=d9bfbbcfcf&e=d19e9fd41c) | 30th March 2022 |   Click on the SSP above to read more, including PSNC guidance on making SSP claims. |  | |  |  |  | | |
| |  |  |  | | --- | --- | --- | | |  | | --- | | Pharmaceutical Services Negotiating Committee   **[Graphical user interface  Description automatically generated](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=fb691477d7&e=d19e9fd41c)** **[Graphical user interface  Description automatically generated](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=a4bb83f11b&e=d19e9fd41c)**  14 Hosier Lane, London, EC1A 9LQ Tel: 0203 1220 810 | Email: [**info@psnc.org.uk**](mailto:info@psnc.org.uk) | |  | | |

